Then, our investigation revealed that the cut-off value (20.0 mg/L) of circulating SAA levels, as defined by ROC analysis of tumor response, may serve as a more accuracy for prognosing factor for survival outcomes of aHCC patients undergoing PD-1 blockade monotherapy compared to utilizing the median level (12.3 mg/L) of SAA (OS: HR 4.44; 95% CI, 1.70–11.57; P = 0.001; PFS: HR 2.93; 95% CI, 1.38–6.21; P = 0.001; Supplementary Fig. 2e, f and Supplementary Table 2). This evidence concerns the gene SAA1 and neoplasm.